The importance of IL28B polymorphism in response to pegylated interferon α and ribavirin in chronic hepatitis caused by HCV genotype 1b

Mach, Tomasz; Cieśla, Andrzej; Sanak, Marek; Głowacki, Mikołaj; Warunek, Wioleta; Owczarek, Danuta; Ciećko-Michalska, Irena

doi:10.5114/pg.2012.27221

Cited by 4 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, as few as 30% of the patients in our study had the C/C variant of IL28B genotype, which according to the numerous recent publications is closely associated with better response to therapy. 11-17, 25,31 The overall results of EVR, ETR, and SVR are similar to those reported by other investigators. 6,8 In the Peg-IFN alfa-2a group, EVR was achieved by 71.7% of the patients, ETR by 81.9%, and SVR by 49.3%.…”

Section: Abbreviations: See Tablesupporting

confidence: 86%

“…In our previous study, we showed that EVR, ETR, and SVR are achieved, respectively, in 38%, 69.7%, and 44.4% of the patients with chronic hepatitis caused by difficult-to-treat HCV genotype 1b and treated with Peg-IFN and ribavirin. 25 The response rate in patients with C/C genotype IL28B was significantly higher (ETR -92.1%, SVR -71.1%) compared with T/C genotype (ETR -67.6%, SVR -40%) and T/T genotype (ETR -52%, SVR -23.5%). 25 Our study confirmed that response to standard treatment of HCV genotype 1b infection in patients from southern Poland depends on the IL28B gene polymorphism.…”

Section: Abbreviations: See Tablementioning

confidence: 86%

“…25 The response rate in patients with C/C genotype IL28B was significantly higher (ETR -92.1%, SVR -71.1%) compared with T/C genotype (ETR -67.6%, SVR -40%) and T/T genotype (ETR -52%, SVR -23.5%). 25 Our study confirmed that response to standard treatment of HCV genotype 1b infection in patients from southern Poland depends on the IL28B gene polymorphism.…”

Section: Abbreviations: See Tablementioning

confidence: 86%

“…Genetic variations of inter leukin (IL) 28B, IL28B, were studied using a previously described method. 25 Briefly, genomic DNA was isolated from peripheral blood samples. A 190 bp amplification product was obtained using a standard polymerase chain reaction (PCR) with primers: 5'-GCC TCT TCC TCC TGC GGG ACA AG and 5'-GCG CGG GCA AGT ATT CAA CCC T Bsh1236I.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b

Mach

Cieśla²,

Warunek³

et al. 2011

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

IntroductIon Treatment of chronic hepatitis C (CHC) with pegylated inter feron (Peg-IFN) and ribavirin leads to sustained viro logical response (SVR) in approximately 50% of the patients. SVR depends on hepatitis C virus (HCV) and host factors, including IL28B genotypes.objEctIvEs The aim of the study was to investigate the therapeutic efficacy of the difficult-to-treat HCV genotype 1b in patients from the south of Poland.PAtIEnts And mEthods A total of 260 adult patients with CHC and HCV genotype 1b were treated with Peg-IFN alfa-2a or Peg-IFN alfa-2b with ribavirin for 48 weeks. Efficacy was assessed at 12 weeks (early viro logical response -EVR), 48 weeks (end-of-treatment response -ETR), and at 6 months (SVR). HCV-RNA, alanine transaminase (ALT), and other bio chemical parameters were measured in serum at baseline and at 12, 48, and 72 weeks of therapy. rEsuLts HCV-RNA levels were 3.72 ±1.17 × 10 6 IU/ml at baseline and decreased significantly at 12 weeks (0.02 ±0.17 × 10 6 IU/ml); there were no differences between the group treated with Peg-INF alfa-2a and the group treated with Peg-INF alfa-2b. ALT was 94.1 ±7.6 IU/l at baseline and decreased significantly at 12 weeks (42.5 ±3.1 IU/l). The overall EVR, ETR, and SVR were achieved by 63.9%, 77.7%, and 48.1% of the patients, respectively. Tolerance of therapy was similar in both groups.concLusIons Efficacy of Peg-IFN alfa-2a with ribavirin is not significantly different from that of Peg-IFN alfa-2b with ribavirin, and SVR was achieved in 48.3% and 44.3% of the patients, respectively. Our study confirms that the efficacy of treatment of patients with HCV genotype 1b from the southern region of Poland is similar to that observed in the overall Polish population. KEy wordschronic hepatitis, HCV genotype 1b, treatment the Polish National Health Fund and conducted according to the relevant recommendations. rEFErEncEs 1 Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005; 5: 558-567.

show abstract

Section: Abbreviations: See Tablesupporting

confidence: 86%

Section: Abbreviations: See Tablementioning

confidence: 86%

Section: Abbreviations: See Tablementioning

confidence: 86%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b

Mach

Cieśla²,

Warunek³

et al. 2011

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…While in the European studies of the Caucasian race nearly 40% incidence of the CC genotype of rs12979860 is observed, the incidence rate for patients in the study population did not exceed 30%. In two independent studies performed on 142 and 97 Polish patients infected with genotype 1 HCV, distribution of rs12979860 CC genotype was 26.8% and 21%, respectively (18, 19). Additionally, the reduced frequency of favorable genotypes rs12979860 CC, rs8099917 TT and rs12980275 AA was showed in our study, when we examined children and adolescents infected with HCV genotype 1 and 4 (14).…”

Section: Discussionmentioning

confidence: 99%

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4

et al. 2013

View full text Add to dashboard Cite

BackgroundThree single nucleotide polymorphisms (SNPs) near interleukin-28B (IL-28B) gene were shown to be highly associated with treatment response (SVR) in patients with chronic hepatitis C virus (HCV) infection. There is limited data about the role of single and combined IL-28B polymorphisms in HCV-infected Polish population.ObjectivesThis study's aim was to determine predictability of three IL-28B gene polymorphisms and other known prognostic factors on the treatment response in HCV genotype 1 and 4 infected Polish patients. The effect of IL-28B polymorphisms on therapy was also compared with other known prognostic factors.Patients and MethodsWe genotyped IL-28B polymorphisms (rs12979860, rs12980275 and rs8099917) by polymerase chain reaction-based restriction fragment length polymorphism assay in a group of 293 patients from which a selected cohort of 174 treatment-naiev patients underwent treatment.ResultsWe showed that rs12979860 CC [odds ratio (OR) = 4.6, P < 0.001], rs12980275 AA (OR = 2.9, P = 0.002) and rs8099917 TT (OR = 2.2, P = 0.016) genotypes were associated with successful treatment compared to the rs12979860 CT-TT, rs12980275 AG-GG and rs8099917 TG-GG, respectively. Patients bearing of IL-28B profile including the three favourable genotypes do not have much chance of a recovery (OR = 3.4, P = 0.002). Except for IL-28B polymorphisms, there was no association of SVR with any other pretreatment clinical data in analyzed group. The correlation of SNPs with other host and viral factors revealed association of favorable genotypes of IL-28B markers with high levels of alanine aminotransferase and baseline HCV viral load.ConclusionsIL-28B polymorphisms were the strongest pretreatment predictors of response to pegylated interferon and ribavirin in Polish patients chronically infected with HCV genotype 1 and 4. This study confirm the strongest impact of IL-28B rs12979860 on SVR, nevertheless rs12980275 AA seems to be more important than rs8099917 TT in predicting positive treatment response.

show abstract

Impact of IL28B genetic variant's and viral genotype on treatment outcome of hepatitis C infected patients

Khan

Shoukat

Mudassar

et al. 2018

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Viral genotype and variation in host genes involved in the immune response may predict the treatment response in patients infected with HCV. The present study was designed to determine the distribution pattern of HCV and host genotypes in Chronic Hepatitis C (CHC) patients and their association with virological response and other risk factors. Methodology: Two hundred and fifty (n = 250) HCV positive patients were included in the study. HCV and Interleukin 28B (IL28B) genotyping was carried out by PCR-RFLP. Results: Viral genotype 3 was the predominant genotype seen in 187 (74.8%) patients. Wild genotype predominated in rs12979860, rs12980275 and rs8099917 SNP of IL28B gene. A significant difference was found in end stage virological response (EVR) between HCV genotype 1 infected patients with wild and variant genotype for rs12980275 and rs8099917 SNPs respectively (P < 0.05). On multivariate analysis all the SNPs were found to be associated with each other (P < 0.05) with rs12980275 SNP associated with history of Jaundice (P < 0.05). Viral genotype 3 was significantly associated with age (< 50 years) and rapid virological response (RVR) while as viral genotype 1 was significantly associated with history of surgery on multivariate analysis (P < 0.05). Conclusions: The viral genotype and IL28B polymorphisms are important factors to personalize antiviral therapy of patients with CHC.

show abstract

The importance of IL28B polymorphism in response to pegylated interferon α and ribavirin in chronic hepatitis caused by HCV genotype 1b

Cited by 4 publications

References 12 publications

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4

Impact of IL28B genetic variant's and viral genotype on treatment outcome of hepatitis C infected patients

Contact Info

Product

Resources

About